Evidence map›Paper›PMID 39264730›Full record

ArticleImmunotherapy2024

A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.

Ben Tran, Mark Voskoboynik, Johanna Bendell, Martin Gutierrez, Charlotte Lemech, Daphne Day, Sophia Frentzas, Ignacio Garrido-Laguna, Nathan Standifer, Fujun Wang and 4 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Facts and Hopes of CD40 Agonists in Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ben TranPeter MacCallum Cancer Centre, Melbourne, 8006, Australia.ORCID 0000-0001-9124-354X
Mark VoskoboynikNucleus Network, Melbourne, 3004, Australia.
Johanna BendellSarah Cannon Research Institute/Tennessee Oncology, Nashville, TN 37203, USA.
Martin GutierrezHackensack University Medical Center, Hackensack, NJ 07601, USA.
Charlotte LemechScientia Clinical Research, Randwick, 2031, Australia.
Daphne DayMonash University, Melbourne, 3004, Australia.
Sophia FrentzasMonash University, Melbourne, 3004, Australia.
Ignacio Garrido-LagunaHuntsman Cancer Institute, Salt Lake City, UT 84132, USA.
Nathan StandiferIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA.
Fujun WangOncology Biometrics, AstraZeneca, Gaithersburg, MD 20878,USA.
Charles FerteAstraZeneca, Gaithersburg, MD 20878,USA.
Yue WangAstraZeneca, Gaithersburg, MD 20878,USA.
Mayukh DasAstraZeneca, Gaithersburg, MD 20878,USA.
Benedito A CarneiroLegorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI 02903,USA.

Funding

AstraZeneca United States
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalCD40 AntigensNeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMaximum Tolerated DoseMiddle AgedTreatment OutcomeAntibodies, MonoclonalCD40 AntigensdurvalumabcancerCD40CD40Lefficacyfusion proteinsafety

Identifiers

PMID39264730
PMCPMC11421296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.